Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Coya Therapeutics, Inc. (COYA)

Coya Therapeutics enrolls 100th patient in Phase 2/3 ALS trial of COYA 302

Neutral Impact 2 of 5 product/contract Written later

Coya Therapeutics said the 100th patient has been enrolled in its ongoing Phase 2/3 ALSTARS Trial of COYA 302 for amyotrophic lateral sclerosis (ALS). The company expects to complete enrollment of 120 participants and report topline data in early Q2 of 2027, based on current enrollment trends.

Key points

  • 100th patient enrolled in the ALSTARS Trial (NCT07161999) as of September 15, 2026
  • Full enrollment of 120 participants expected, with topline data targeted for early Q2 2027
  • Primary endpoint is change in ALSFRS-R total score from baseline to Week 24 compared with placebo

The filing

CompanyCoya Therapeutics, Inc. (COYA)
Form8-K, current report
Filed with the SECSep 15, 2026, 8:15 AM ET
Accession number0001193125-26-391378

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.